twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2024
vol. 126
 
Share:
Share:
abstract:
Review paper

Macular abnormalities in retinitis pigmentosa. Management and treatment

Magdalena Durajczyk
1
,
Katarzyna Seredyńska
1
,
Wojciech Lubiński
1

  1. 2nd Department of Ophthalmology, Pomeranian Medical University in Szczecin, Poland
KLINIKA OCZNA 2024, 126, 2: 59-64
Online publish date: 2024/05/22
View full text Get citation
 
PlumX metrics:
Aim
To review the current state of knowledge on macular in retinitis pigmentosa, current treatment methods and management.

Material and methods
Analysis of literature available on PubMed. Presentation of own treatment results.

Results
Macular lesions occur in 11.5% to 59.7% of patients with pigmentary degeneration. The most commonly observed macular abnormalities include cystoid macular edema, epiretinal membranes, vitreomacular traction syndrome, and full-thickness macular holes. In conservative treatment, topical carbonic anhydrase inhibitors and steroids are the most effective. The best surgical treatment outcomes have been obtained for macular holes. Conservative and surgical treatment outcomes vary and depend on the stage of retinitis pigmentosa.

Conclusions
Macular abnormalities are often observed in patients with retinitis pigmentosa. arbonic anhydrase blockers and steroids can be effective in treating cystoid macular edema. Surgical treatment can improve macular morphology but improvement in visual function is limited due to long-term retinal dysfunction and progression of the underlying disease.

keywords:

retinitis pigmentosa, macular abnormalities, present knowledge

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.